Replies to post #45343 on RespireRx Pharmaceuticals Inc (RSPI)

[NeutrinoKid]

Maybe KRM-II-81 has had better oral availability, but the Ampakines had been beset by delivery and/or potency/toxicity issues since even when that company was called Cortex pharm. That was why the first batch of “CX-“ drugs were shut down. That is a key hint to make sense of that company’s history. The literature on CX compounds is surprisingly diverse and extensive, and goes back to the 1980s.